Search results
Showing 6121 to 6135 of 8314 results
Recommendation ID CG184/5 Question What specialist investigations should be conducted to exclude a diagnosis of functional dyspepsia in
Recommendation ID CG184/4 Question What specialist management is effective for people whose symptoms do not respond to PPIs despite optimum
Recommendation ID TA235/1 Question Further studies on the clinical effectiveness of mifamurtide when combined with the chemotherapy typical
Recommendation ID NG63/3 Question High-risk groups:- What interventions to prevent infection and reduce antimicrobial resistance are effective
Recommendation ID NG63/5 Question Older people in day and residential care:- How effective are interventions in day and residential care
Recommendation ID NG63/4 Question Workplace:- How effective are interventions in the workplace that aim to prevent infection and reduce
Recommendation ID NG63/2 Question Behavioural strategies and programmes:- What is the feasibility and effectiveness of specific behavioural
Recommendation ID NG63/1 Question Cost effectiveness:- What is the cost effectiveness of interventions to prevent infection and promote
Recommendation ID NG36/4 Question Enteral nutrition support:- What specific clinical and non-clinical factors allow risk stratification
Recommendation ID NG36/3 Question Unknown primary of presumed upper aerodigestive tract origin:- In people with CUADT of unknown primary
Recommendation ID NG36/1 Question Systemic imaging – who and why?:- What factors determine the risk of a person presenting with CUADT having
Recommendation ID NG36/5 Question Follow-up:- What is the optimal method, frequency and duration of follow-up for people who are disease-free
Recommendation ID NG36/2 Question HPV testing:- What is the comparative effectiveness of single-step laboratory diagnostic tests to identify
Resources, case studies and patient decision aids to show how you can use evidence to improve care and services
Hundreds could benefit from life saving blood cancer treatment recommended by NICE
People with a rare and aggressive blood cancer will benefit from a potentially life saving treatment, following NICE’s recommendation of a CAR-T (chimeric antigen receptor T-cell) treatment developed by a British spinout company.